Epithalon + Pinealon is a two-peptide catalog product that puts two of the best-known "peptide bioregulators" into one vial. Both peptides come out of the same Russian research program, and both carry the same caveat: most of the literature comes from one group and has rarely been replicated independently [1][2]. This monograph covers what each component is, what the published work on each one reports, and what is and is not known about the combination. The short answer to the last question is that the fixed combination has not been studied.
Composition
The catalog listing is "Epithalon / Pinealon (50mg)". That is the only composition information on the label, and this monograph does not infer a per-component split from it. Two peptides are in the vial:
- Epithalon (also spelled Epitalon), a synthetic tetrapeptide, Ala-Glu-Asp-Gly (AEDG). It was designed to match the amino-acid composition of epithalamin, a bovine pineal-gland extract [1][3].
- Pinealon, a synthetic tripeptide, Glu-Asp-Arg (EDR), from the same bioregulator series [2][7].
Both are short, defined peptides with distinct molecular weights, so each can be identified separately by mass spectrometry.
What each component contributes
Epithalon. A 2025 review describes Epithalon as studied in vitro, in vivo and in silico over roughly 25 years. Reported findings include effects on melatonin synthesis, interleukin-2 mRNA, thymocyte mitogenic activity, and the activity of several enzymes, telomerase among them. The same review says it is still uncertain whether these are the peptide's only mechanisms, and that physico-chemical and structural studies of it remain limited [3]. In human cell lines, one study reported telomere-length extension that depended on concentration. In normal cells this went through hTERT and telomerase upregulation; in breast-cancer cell lines it went through alternative lengthening of telomeres (ALT) [4]. In human gingival mesenchymal stem cells, Epithalon increased neurogenic differentiation markers, and molecular modelling suggested it binds histone H1 [5]. The VialTalk Epithalon monograph rates the telomerase and anti-aging claims as not robustly established outside a narrow literature [1].
Pinealon. In cerebellar granule cells, neutrophils and PC12 cells, Pinealon limited reactive-oxygen-species accumulation and necrotic cell death under oxidative stress, and it altered ERK1/2 activation and the cell cycle. The authors read this as evidence of a direct interaction with the genome [6]. A review of the EDR peptide proposes that it enters cells and binds histones and/or nucleic acids, which would affect MAPK/ERK signalling, apoptotic proteins and antioxidant enzymes. The review frames this as relevant to Alzheimer's disease pathogenesis [7]. In aged rats under hypoxia and hypothermia stress models, Pinealon and the comparator Cortexin both changed behavioural and neurochemical measures. Cortexin had the stronger effect on free-radical processes and caspase-3 activity [8].
Shared mechanistic hypothesis. The two peptides overlap mainly in a proposed mechanism, not in demonstrated combined effects. One cell study found that fluorescently labelled Epithalon and Pinealon both reached the nucleus of HeLa cells and bound DNA oligonucleotides in a sequence-dependent way, with a preference for CNG/CAG-containing sequences [9]. The research program behind both peptides treats this sequence-specific DNA binding as the basis for its "bioregulator" model. The model is a hypothesis from one research program, not an independently established mechanism [2][9].
Combination evidence — the honest boundary
A PubMed search for "epithalon pinealon" (October 2026) returned three records [9][10][11]. None of them tests the fixed Epithalon + Pinealon combination as a product:
- One is a cell study in which each peptide was tested separately, alongside other short peptides, for nuclear penetration and DNA binding [9].
- One is an organotypic rat pineal-culture study that tested AEDG (Epithalon), EDR (Pinealon) and other short peptides one at a time. Only AEDG stimulated CGRP synthesis by pinealocytes. AEDG and Lys-Glu-Asp, but not EDR, increased the proliferation marker Ki-67 [10].
- One is a 2026 orthopaedics review that groups Epithalon and Pinealon with other "recovery-enhancing" peptides and notes that clinical trials are currently lacking [11].
So no published animal, cell or human study has tested Epithalon and Pinealon given together. Nothing has been published on interaction, synergy, antagonism or the stability of the co-formulated peptides. The evidence for each component is mostly cell and animal work, much of it from the Khavinson group [1][2][3]. No randomized human trial of either peptide was found in the sources used here. The one direct side-by-side comparison [10] found the two peptides acted differently in pineal tissue, which argues against assuming they are interchangeable or additive.
Research context
Researchers usually come across this blend through the "pineal bioregulator" idea: Epithalon as the pineal/telomerase peptide and Pinealon as the neuronal/antioxidant peptide. Neither peptide is FDA- or EMA-approved [1][2]. Any research use of this product is testing an uncharacterised mixture, and the literature on each component cannot be carried over to it.
Storage and handling
Keep the lyophilized vial dry, sealed, refrigerated and protected from light, and avoid repeated temperature cycling. There are no published stability data for the two peptides co-lyophilized together.
Quality and COA considerations
A meaningful COA for a two-peptide vial should report separate mass-spectrometry identity for each component (AEDG tetrapeptide and EDR tripeptide), HPLC purity for each, and a fill breakdown showing the amount of each peptide present against the "50mg" label. A single combined purity figure cannot show whether both peptides are present or in what proportion. As the component monographs note, verifying identity and purity is straightforward for peptides this short. The harder problem is the evidence base, which no COA addresses [1][2].
Key references
- [1] VialTalk monograph — Epithalon — https://vialtalk.com/forum/peptide-research-library/epithalon-research-monograph-telomerase-pineal-evidence
- [2] VialTalk monograph — Pinealon — https://vialtalk.com/forum/peptide-research-library/pinealon-research-monograph-short-peptide-bioregulator
- [3] Overview of Epitalon — highly bioactive pineal tetrapeptide (review, 2025) — https://pubmed.ncbi.nlm.nih.gov/40141333/
- [4] Epitalon increases telomere length in human cell lines (2025) — https://doi.org/10.1007/s10522-025-10315-x
- [5] AEDG peptide (Epitalon) stimulates gene expression during neurogenesis (2020) — https://pubmed.ncbi.nlm.nih.gov/32019204/
- [6] Pinealon increases cell viability by suppression of free radical levels (2011) — https://pubmed.ncbi.nlm.nih.gov/21978084/
- [7] EDR peptide: gene expression and protein synthesis regulation in Alzheimer's disease (review, 2020) — https://pubmed.ncbi.nlm.nih.gov/33396470/
- [8] Pinealon and Cortexin in 18-month aged rats (2015) — https://pubmed.ncbi.nlm.nih.gov/28509493/
- [9] Fedoreyeva et al. 2011 — short peptides penetrate the nucleus and interact with DNA — https://pubmed.ncbi.nlm.nih.gov/22117547/
- [10] Khavinson et al. 2011 — short peptides in organotypic pineal cell culture — https://pubmed.ncbi.nlm.nih.gov/22803060/
- [11] Rahman et al. 2026 — Therapeutic peptides in orthopaedics (review) — https://pubmed.ncbi.nlm.nih.gov/41490200/
Research-use note: This is an educational summary of the published research on Epithalon and Pinealon as individual compounds. The Epithalon + Pinealon combination has not been evaluated in any published study, and neither component is an approved drug. Nothing here is medical advice or a usage recommendation.